Press release
Investigation announced for Investors who purchased shares of Chinook Therapeutics, Inc. (NASDAQ: KDNY) concerning potential Wrongdoing
An investigation on behalf of investors in Chinook Therapeutics, Inc. (NASDAQ: KDNY) shares over potential wrongdoing.
Investors who purchased shares of Chinook Therapeutics, Inc. (NASDAQ: KDNY) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Chinook Therapeutics, Inc. officers and directors breached their fiduciary duties and caused damage to the company and its shareholders.
Seattle, WA based Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. Chinook Therapeutics, Inc. reported that its annual Total Revenue declined from $51.62 million in 2021 to $6.12 million in 2022, and that its Net Loss increased from $102.93 million in 2021 to $187.86 million in 2022.
On May 16, 2023, Muddy Waters Research published a report alleging that Chinook's lead product candidate, atrasentan, "has been shown to be harmful to patients' cardiovascular health," and that "AbbVie and Chinook seem to have systemically manipulated research findings and presentation on atrasentan to obscure these trial results."
Shares of Chinook Therapeutics, Inc. (NASDAQ: KDNY) declined from $23.40 per share on May 12, 2023, to as low as $19.20 per share on May 16, 2023.
Those who purchased shares of Chinook Therapeutics, Inc. (NASDAQ: KDNY) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Investors who purchased shares of Chinook Therapeutics, Inc. (NASDAQ: KDNY) concerning potential Wrongdoing here
News-ID: 3263558 • Views: …
More Releases from Shareholders Foundation
ALERT: Lawsuit filed for Investors who SOLD shares of Sina Corporation (formerly …
An investor, who sold shares of Sina Corporation (formerly NASDAQ: SINA) in the merger between Seina Corporation and TuSimple Holdings, Inc, filed a lawsuit over alleged violations of Federal Securities Laws by Sina Corporation (formerly NASDAQ: SINA in connection with certain allegedly false and misleading statements made.
If you sold a significant amount of shares of Sina Corporation (formerly NASDAQ: SINA) between October 13, 2020 and March 22, 2021, you have…
Lawsuit Alert: Investors who lost money with shares of Fluor Corporation (NYSE: …
An investor, who purchased shares of Fluor Corporation (NYSE: FLR), filed a lawsuit alleged violations of Federal Securities Laws by Fluor Corporation in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Fluor Corporation (NYSE: FLR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 14, 2025. NYSE: FLR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779…
Investigation announced for Long-Term Investors in shares of Sable Offshore Corp …
An investigation was announced for long-term investors in shares of Sable Offshore Corp. (NYSE: SOC) concerning potential breaches of fiduciary duties by certain directors of Sable Offshore Corp.
Investors who are current long term investors in Sable Offshore Corp. (NYSE: SOC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in…
Lawsuit filed for Investors who lost money with shares of Lantheus Holdings, Inc …
An investor, who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH), filed a lawsuit over alleged violations of Federal Securities Laws by Lantheus Holdings, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) have certain options and for certain investors are short and strict deadlines running. Deadline: November 10, 2025. NASDAQ: LNTH investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
More Releases for Chinook
Proteinuria Therapeutics Market Report: Insights, Analysis & Opportunities to 20 …
The latest Proteinuria Therapeutics Market research report offers crucial insights into how the industry is evolving, highlighting key drivers of growth and the main revenue streams expected between 2025 and 2032. It analyzes market size, revenue, production, and CAGR using validated methodologies to ensure precision. The Industry compass guiding business through the complexities of the market, presenting not only the current landscape but also the latest innovations shaping its future.…
Primary Hyperoxaluria Clinical Trials, Companies, Therapeutic Assessment, Therap …
DelveInsight's, "Primary Hyperoxyaluria - Pipeline Insight, 2025" report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Primary Hyperoxyaluria pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
According to DelveInsight, the Primary Hyperoxaluria pipeline features over 6…
Proteinuria Therapeutics Market Growth in Future Scope 2025-2032 | GlaxoSmithKli …
The latest qualitative research report (2025-2032) on the Proteinuria Therapeutics Market, published by Coherent Market Insights, provides an in-depth analysis of key market trends, drivers, challenges, and competitive dynamics. It evaluates market size, revenue, production, and CAGR through validated methodologies to ensure accuracy. This report highlighting technological innovations, pricing shifts, consumer preferences, and investment opportunities, the report enables strategic and informed business decisions.
Request a Sample Copy: https://www.coherentmarketinsights.com/insight/request-sample/4491
Focused on growth and…
Proteinuria Therapeutics Market Projected To Witness Substantial Growth, 2025-20 …
A new study titled Proteinuria Therapeutics Market 2025, published by the Coherent Market Insights, offers information on regional and global markets that is expected to increase in value between 2025 and 2032. The study of the Proteinuria Therapeutics Market provides an in-depth analysis of the market for the projected time frame (2025-2032). There are other parts in the study that moreover analyse the trends and variables that are significantly influencing…
Nephrotic Syndrome Market Insights 2034 by Delveinsight | Vertex Pharmaceuticals …
The market size of Nephrotic Syndrome is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as Vertex Pharmaceuticals, Chinook Therapeutics, Novartis, Boehringer Ingelheim, Hoffmann-La Roche, Biogen
[Nevada, United States] - DelveInsight's "Nephrotic Syndrome Market Insights, Epidemiology, and Market Forecast 2034." report offers a detailed examination of Nephrotic Syndrome, covering historical and predicted epidemiology, market trends, and treatment…
Investigation announced for Investors who lost money with shares of Chinook Ther …
An investigation was announced over potential securities laws violations by Chinook Therapeutics, Inc. in connection with certain financial statements.
Investors who purchased shares of Chinook Therapeutics, Inc. (NASDAQ: KDNY), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by Chinook Therapeutics, Inc. regarding its business, its prospects and its operations were…
